P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY

• Nizar J Bahlis,
• Christy Samaras,
• Donna Reece,
• Michael Sebag,
• Jeffrey Matous,
• Jesus Berdeja,
• Jesse Shustik,
• Gary Schiller,
• Siddhartha Ganguly,
• Kevin Song,
• Christopher S. Seet,
• Mirelis Acosta-Rivera,
• Donald Quick,
• Bertrand Anz,
• Gustavo Fonseca,
• Unicel-Anne Flores,
• Hongjuan Liu,
• Christian Gentili,
• David Siegel

Affiliations

Nizar J Bahlis

1 University of Calgary, Calgary, Canada

Christy Samaras

2 Cleveland Clinic, Cleveland, OH, United States

Donna Reece

3 Princess Margaret Hospital, Toronto, ON, Canada

Michael Sebag

4 McGill University Health Centre, Montreal, QC, Canada

Jeffrey Matous

5 Saint Luke’s Medical Center, Denver, CO, United States

Jesus Berdeja

6 Sarah Cannon Research Institute, Nashville, TN, United States

Jesse Shustik

7 Fraser Valley Cancer Centre, Surrey, BC, Canada

Gary Schiller

8 UCLA Medical Center, Los Angeles, CA, United States

Siddhartha Ganguly

9 Houston Methodist Hospital Neal Cancer Center, Houston, TX, United States

Kevin Song

10 Vancouver General Hospital, Vancouver, BC, Canada

Christopher S. Seet

8 UCLA Medical Center, Los Angeles, CA, United States

Mirelis Acosta-Rivera

11 Fundacion de Investigacion de Diego, San Juan, Puerto Rico

Donald Quick

12 Joe Arrington Cancer Research and Treatment Center, Lubbock, TX, United States

Bertrand Anz

13 Tennessee Oncology, Nashville, TN, United States

Gustavo Fonseca

14 Florida Cancer Specialists, Lecanto, FL, United States

Unicel-Anne Flores

15 Bristol Myers Squibb, Princeton, NJ, United States

Hongjuan Liu

15 Bristol Myers Squibb, Princeton, NJ, United States

Christian Gentili

16 Bristol Myers Squibb, Boudry, Switzerland

David Siegel

17 John Theurer Cancer Center, Hackensack, NJ, United States